Founded in 1986 by two former employees of Abbott France, Theradiag has been dedicated, at first, to distributing in vitro diagnostics, specifically for autoimmune diseases. With more than 25 years experience of developing, manufacturing, and marketing innovative in-vitro diagnostics, Theradiag is now strengthening its presence in theranostics. Our new name, Theradiag, illustrates this approach. With CE marking in 2010 and the launch in 2011 of the first Lisa-Tracker kits, we are expanding this panel by developing and launching new kits. Our goal is to offer clinicians and patients a wide range of biotherapy monitoring kits. We have built the foundations for this new activity based on our knowledge of autoimmune diseases. In the coming months, we will be extending our offer to assist in the monitoring of biotherapies in other treatment areas, such as infectious diseases and cancer. We will also continue to develop our traditional activity in IVD, and specifically autoimmunity and innovative oncogenetic diagnostics. This technological and innovative evolution will allow Theradiag to better serve its clients and contribute to improving the bio-therapeutic treatments of today and the future.
Croissy-Beaubourg, FR
69 (est)

Theradiag Locations

Croissy-Beaubourg, FR

Theradiag Metrics

Theradiag Summary

Founding Date


Market capitalization

€22.4 M

Closing share price


Theradiag Market Value History